Sempra shares fell 3.7% after earnings, with the clearest concern in the outlook: management said California segment earnings could land toward the low end of its 2027 guidance range if regulators do not reverse a proposed decision on capital attrition rates. The company also flagged regulatory and execution risks even as it pointed to substantial planned growth at Oncor.
Shares declined 2.3% following Sempra’s Q1 report as investors digested a largely in-line quarter with no clear catalyst to drive the stock higher, amid ongoing execution on planned infrastructure investments and regulatory approvals but without material margin expansion or forward guidance updates.
Sempra's Q3 2025 earnings reflect strong operational execution and strategic advancements, with adjusted EPS rising to $1.11, while the company affirms its favorable growth projections for the upcoming years.